February 2, 2022

The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy goals of reducing the death rate from cancer and improving the experience of patients and families living with cancer.

February 1, 2022

On February 1, 2022, the American Society of Clinical Oncology (ASCO) and the American Cancer Society (ACS) initiated a collaboration to ensure that people can easily find the trusted, expert-approved cancer content they need when turning to either organization for information. As an initial step, the organizations are cross-sharing select cancer prevention, screening, and survivorship resources on their patient and consumer education websites, Cancer.Net and Cancer.org.

January 24, 2022

In patients with advanced gastrointestinal stromal tumors (GIST) that progressed on or were intolerant to imatinib, the efficacy of ripretinib was comparable to sunitinib. These findings from the INTRIGUE trial were presented during the January session of the American Society of Clinical Oncology (ASCO) Plenary Series. 

January 18, 2022

Results from the randomized international phase III TOPAZ-1 trial showed that the checkpoint immunotherapy durvalumab (Imfinzi) plus chemotherapy drugs gemcitabine and cisplatin significantly improved overall survival in patients with advanced biliary tract cancer compared to patients who received a placebo plus the chemotherapy drugs. Biliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.

January 18, 2022

Results from the randomized international phase III HIMALAYA trial showed that a combination of durvalumab (Imfinzi) plus the experimental drug tremelimumab, both immunotherapies, significantly improved overall survival in patients with advanced, unresectable hepatocellular carcinoma, the most common type of liver cancer, compared to patients who received only sorafenib (Nexavar). 

January 14, 2022

In many areas of the United States, the healthcare system is facing critical workforce shortages. The American Society of Clinical Oncology (ASCO) encourages public health officials and healthcare facilities to follow Centers for Disease Control and Prevention (CDC) guidelines for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-CoV-2. These guidelines allow for different levels of restrictions on staffing based on the level of shortages being experienced. However, in making these decisions, ASCO strongly encourages institutions and public health agencies to recognize the greater risk of infection and adverse outcomes that immune-suppressed individuals, including many patients with cancer, face from SARS-CoV-2 and to make decisions about staffing for the care of those individuals with thoughtful consideration of that greater risk. Unless no alternative exists, COVID-19 positive health workers, even if asymptomatic, should not be assigned to care for patients with cancer

December 23, 2021

Findings on combination therapies with immunotherapy drugs for patients with biliary tract cancer and hepatocellular carcinoma will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 650 abstracts that will be presented at the Symposium. 

December 17, 2021

Alexandria, VA -- ASCO has elected Lynn M. Schuchter, MD, FASCO, a long-time member and volunteer, to serve as its President beginning in June 2023. Dr. Schuchter will take office as President-Elect immediately after the ASCO Annual Meeting in Chicago in June 2022. Seven new members were also elected to the ASCO Board of Directors and Nominating Committee. This is the first ASCO election to take place under the recently amended Bylaws that were approved by the members last year. These amendments were designed to increase diversity and representation among ASCO elected leaders and have resulted in one of the most diverse groups of incoming Board and Nominating Committee members in ASCO history.

December 16, 2021

Fifty years ago, just a few days before the new year, former President Richard Nixon signed into law the National Cancer Act (NCA), setting a clear national priority to conquer cancer.

December 14, 2021

Building on its long history of advancing health equity in cancer care, the American Society of Clinical Oncology (ASCO) today released, “The ASCO Equity, Diversity, and Inclusion (EDI) Action Plan: A Legacy of Commitment, A Future of Promise for Individuals with Cancer.” The plan, which was approved earlier this year by ASCO’s Board of Directors, aims to infuse equity into all of the organization’s activities, with the goal of making meaningful progress that improves the quality of cancer care.

December 10, 2021

The Association for Clinical Oncology (ASCO) appreciates that Congress passed legislation to prevent what would have been devastating reimbursement cuts for Medicare services from going into effect on January 1, 2022. With this short-term fix in place, we call on Congress and the Administration to work with healthcare providers on a true long-term solution for sustainable Medicare reimbursement that supports access to cancer care for all Americans. 

December 3, 2021

The Association for Clinical Oncology (ASCO) calls on Congress to pass legislation that will prevent devastating reimbursement cuts to Medicare services set to begin on January 1. Failure to do so will significantly compromise patient access to lifesaving cancer care during an ongoing and unprecedented pandemic. 

November 15, 2021

Two studies from the inaugural ASCO Plenary Series session will highlight the latest practice-changing results in advanced melanoma and digital symptom monitoring. The studies will be presented in a live broadcast session on November 16, 2021, at 3:00 PM ET. 

October 5, 2021

The Association for Clinical Oncology (ASCO) congratulates Dr. Francis Collins on his long and impactful tenure as Director of the National Institutes of Health (NIH).

September 20, 2021

Interventions that paired community-based health workers with low-income and minority patients with cancer improved quality of life and may be a more effective and sustainable way to ensure equitable cancer care, according to a study to be presented as part of the 2021 ASCO Quality Care Symposium.